ID   NCPR_HUMAN              Reviewed;         677 AA.
AC   P16435; Q16455; Q197M5; Q8N181; Q9H3M8; Q9UDT3;
DT   01-AUG-1990, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 2.
DT   10-MAY-2017, entry version 198.
DE   RecName: Full=NADPH--cytochrome P450 reductase {ECO:0000255|HAMAP-Rule:MF_03212};
DE            Short=CPR {ECO:0000255|HAMAP-Rule:MF_03212};
DE            Short=P450R {ECO:0000255|HAMAP-Rule:MF_03212};
DE            EC=1.6.2.4 {ECO:0000255|HAMAP-Rule:MF_03212};
GN   Name=POR {ECO:0000255|HAMAP-Rule:MF_03212}; Synonyms=CYPOR;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT VAL-500.
RX   PubMed=1550342; DOI=10.1016/0003-9861(92)90152-M;
RA   Shephard E.A., Palmer C.N., Segall H.J., Phillips I.R.;
RT   "Quantification of cytochrome P450 reductase gene expression in human
RT   tissues.";
RL   Arch. Biochem. Biophys. 294:168-172(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Liver;
RA   Czerwinski M., Sahni M., Madan A., Parkinson A.;
RT   "Polymorphism of human CYPOR: expression of new allele.";
RL   Submitted (APR-2000) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Murakami H.O., Ogawa H., Nisimoto Y.;
RT   "cDNA cloning and characterization of NADPH-cytochrome P-450 reductase
RT   in human HL-60 cell.";
RL   Submitted (NOV-2000) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS LEU-225; ASN-252 AND
RP   VAL-500.
RG   NIEHS SNPs program;
RL   Submitted (MAY-2006) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R.,
RA   Wylie K., Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H.,
RA   Sun H., Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A.,
RA   Vanbrunt A., Nguyen C., Du F., Lamar B., Courtney L., Kalicki J.,
RA   Ozersky P., Bielicki L., Scott K., Holmes A., Harkins R., Harris A.,
RA   Strong C.M., Hou S., Tomlinson C., Dauphin-Kohlberg S.,
RA   Kozlowicz-Reilly A., Leonard S., Rohlfing T., Rock S.M.,
RA   Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., Strowmatt C.,
RA   Latreille P., Miller N., Johnson D., Murray J., Woessner J.P.,
RA   Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., Spieth J.,
RA   Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., Cook L.L.,
RA   Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., Mardis E.R.,
RA   Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K.,
RA   Simms E., Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S.,
RA   Baertsch R.A., Brent M.R., Keibler E., Flicek P., Bork P., Suyama M.,
RA   Bailey J.A., Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R.,
RA   Eddy S.R., McPherson J.D., Olson M.V., Eichler E.E., Green E.D.,
RA   Waterston R.H., Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS LEU-225 AND
RP   VAL-500.
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   PROTEIN SEQUENCE OF 2-677, CLEAVAGE OF INITIATOR METHIONINE, AND
RP   ACETYLATION AT GLY-2.
RC   TISSUE=Liver;
RX   PubMed=2513880; DOI=10.1021/bi00447a054;
RA   Haniu M., McManus M.E., Birkett D.J., Lee T.D., Shively J.E.;
RT   "Structural and functional analysis of NADPH-cytochrome P-450
RT   reductase from human liver: complete sequence of human enzyme and
RT   NADPH-binding sites.";
RL   Biochemistry 28:8639-8645(1989).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-63, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.93 ANGSTROMS) OF 61-241 IN COMPLEX WITH FMN.
RX   PubMed=10048323; DOI=10.1110/ps.8.2.298;
RA   Zhao Q., Modi S., Smith G., Paine M., McDonagh P.D., Wolf C.R.,
RA   Tew D., Lian L.Y., Roberts G.C., Driessen H.P.;
RT   "Crystal structure of the FMN-binding domain of human cytochrome P450
RT   reductase at 1.93 A resolution.";
RL   Protein Sci. 8:298-306(1999).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 232-677 IN COMPLEX WITH FAD.
RX   PubMed=19483672; DOI=10.1038/embor.2009.82;
RA   Aigrain L., Pompon D., Morera S., Truan G.;
RT   "Structure of the open conformation of a functional chimeric NADPH
RT   cytochrome P450 reductase.";
RL   EMBO Rep. 10:742-747(2009).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (1.40 ANGSTROMS) OF 241-677 IN COMPLEX WITH FAD;
RP   FMN AND NADP.
RX   PubMed=21808038; DOI=10.1073/pnas.1106632108;
RA   Xia C., Panda S.P., Marohnic C.C., Martasek P., Masters B.S.,
RA   Kim J.J.;
RT   "Structural basis for human NADPH-cytochrome P450 oxidoreductase
RT   deficiency.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:13486-13491(2011).
RN   [15]
RP   VARIANT ABS1 HIS-454.
RX   PubMed=15264278; DOI=10.1002/ajmg.a.30169;
RA   Adachi M., Tachibana K., Asakura Y., Yamamoto T., Hanaki K., Oka A.;
RT   "Compound heterozygous mutations of cytochrome P450 oxidoreductase
RT   gene (POR) in two patients with Antley-Bixler syndrome.";
RL   Am. J. Med. Genet. A 128:333-339(2004).
RN   [16]
RP   VARIANTS ABS1 HIS-454; CYS-575 AND 608-LEU--TRP-617 DELINS ARG, AND
RP   VARIANT VAL-500.
RX   PubMed=15483095; DOI=10.1210/jc.2004-0810;
RA   Fukami M., Horikawa R., Nagai T., Tanaka T., Naiki Y., Sato N.,
RA   Okuyama T., Nakai H., Soneda S., Tachibana K., Matsuo N., Sato S.,
RA   Homma K., Nishimura G., Hasegawa T., Ogata T.;
RT   "Cytochrome P450 oxidoreductase gene mutations and Antley-Bixler
RT   syndrome with abnormal genitalia and/or impaired steroidogenesis:
RT   molecular and clinical studies in 10 patients.";
RL   J. Clin. Endocrinol. Metab. 90:414-426(2005).
RN   [17]
RP   VARIANTS DISPORD ASP-178; PRO-284; HIS-454 AND TYR-566, AND
RP   CHARACTERIZATION OF VARIANTS DISPORD ASP-178; PRO-284; HIS-454 AND
RP   TYR-566.
RX   PubMed=15220035; DOI=10.1016/S0140-6736(04)16503-3;
RA   Arlt W., Walker E.A., Draper N., Ivison H.E., Ride J.P., Hammer F.,
RA   Chalder S.M., Borucka-Mankiewicz M., Hauffa B.P., Malunowicz E.M.,
RA   Stewart P.M., Shackleton C.H.L.;
RT   "Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase
RT   and human androgen synthesis: analytical study.";
RL   Lancet 363:2128-2135(2004).
RN   [18]
RP   VARIANTS ABS1 PRO-284; HIS-454 AND GLU-489, VARIANTS DISPORD TYR-566
RP   AND PHE-605, CHARACTERIZATION OF VARIANTS ABS1 PRO-284; HIS-454 AND
RP   GLU-489, AND CHARACTERIZATION OF VARIANTS DISPORD TYR-566 AND PHE-605.
RX   PubMed=14758361; DOI=10.1038/ng1300;
RA   Flueck C.E., Tajima T., Pandey A.V., Arlt W., Okuhara K., Verge C.F.,
RA   Jabs E.W., Mendonca B.B., Fujieda K., Miller W.L.;
RT   "Mutant P450 oxidoreductase causes disordered steroidogenesis with and
RT   without Antley-Bixler syndrome.";
RL   Nat. Genet. 36:228-230(2004).
RN   [19]
RP   VARIANT HIS-454.
RX   PubMed=27610946; DOI=10.1002/humu.23116;
RA   Igarashi M., Takasawa K., Hakoda A., Kanno J., Takada S., Miyado M.,
RA   Baba T., Morohashi K.I., Tajima T., Hata K., Nakabayashi K.,
RA   Matsubara Y., Sekido R., Ogata T., Kashimada K., Fukami M.;
RT   "Identical NR5A1 Missense Mutations in Two Unrelated 46,XX Individuals
RT   with Testicular Tissues.";
RL   Hum. Mutat. 38:39-42(2017).
CC   -!- FUNCTION: This enzyme is required for electron transfer from NADP
CC       to cytochrome P450 in microsomes. It can also provide electron
CC       transfer to heme oxygenase and cytochrome B5. {ECO:0000255|HAMAP-
CC       Rule:MF_03212}.
CC   -!- CATALYTIC ACTIVITY: NADPH + n oxidized hemoprotein = NADP(+) + n
CC       reduced hemoprotein. {ECO:0000255|HAMAP-Rule:MF_03212}.
CC   -!- COFACTOR:
CC       Name=FAD; Xref=ChEBI:CHEBI:57692;
CC         Evidence={ECO:0000255|HAMAP-Rule:MF_03212,
CC         ECO:0000269|PubMed:21808038};
CC       Note=Binds 1 FAD per monomer. {ECO:0000255|HAMAP-Rule:MF_03212,
CC       ECO:0000269|PubMed:21808038};
CC   -!- COFACTOR:
CC       Name=FMN; Xref=ChEBI:CHEBI:58210;
CC         Evidence={ECO:0000255|HAMAP-Rule:MF_03212,
CC         ECO:0000269|PubMed:21808038};
CC       Note=Binds 1 FMN per monomer. {ECO:0000255|HAMAP-Rule:MF_03212,
CC       ECO:0000269|PubMed:21808038};
CC   -!- INTERACTION:
CC       P00181:CYP2C2 (xeno); NbExp=4; IntAct=EBI-726554, EBI-4320576;
CC       O00264:PGRMC1; NbExp=5; IntAct=EBI-726554, EBI-1045534;
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane
CC       {ECO:0000255|HAMAP-Rule:MF_03212}; Single-pass membrane protein
CC       {ECO:0000255|HAMAP-Rule:MF_03212}; Cytoplasmic side
CC       {ECO:0000255|HAMAP-Rule:MF_03212}.
CC   -!- DISEASE: Antley-Bixler syndrome, with genital anomalies and
CC       disordered steroidogenesis (ABS1) [MIM:201750]: A disease
CC       characterized by the association of Antley-Bixler syndrome with
CC       steroidogenesis defects and abnormal genitalia. Antley-Bixler
CC       syndrome is characterized by craniosynostosis, radiohumeral
CC       synostosis present from the perinatal period, midface hypoplasia,
CC       choanal stenosis or atresia, femoral bowing and multiple joint
CC       contractures. {ECO:0000269|PubMed:14758361,
CC       ECO:0000269|PubMed:15264278, ECO:0000269|PubMed:15483095}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Disordered steroidogenesis due to cytochrome P450
CC       oxidoreductase deficiency (DISPORD) [MIM:613571]: A disorder
CC       resulting in a rare variant of congenital adrenal hyperplasia,
CC       with apparent combined P450C17 and P450C21 deficiency and
CC       accumulation of steroid metabolites. Affected girls are born with
CC       ambiguous genitalia, but their circulating androgens are low and
CC       virilization does not progress. Conversely, affected boys are
CC       sometimes born undermasculinized. Boys and girls can present with
CC       bone malformations, in some cases resembling the pattern seen in
CC       patients with Antley-Bixler syndrome.
CC       {ECO:0000269|PubMed:14758361, ECO:0000269|PubMed:15220035}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the NADPH--cytochrome P450 reductase
CC       family. {ECO:0000255|HAMAP-Rule:MF_03212}.
CC   -!- SIMILARITY: In the N-terminal section; belongs to the flavodoxin
CC       family. {ECO:0000255|HAMAP-Rule:MF_03212}.
CC   -!- SIMILARITY: In the C-terminal section; belongs to the flavoprotein
CC       pyridine nucleotide cytochrome reductase family.
CC       {ECO:0000255|HAMAP-Rule:MF_03212}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH34277.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/por/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; S90469; AAB21814.1; -; mRNA.
DR   EMBL; AF258341; AAG09798.1; -; mRNA.
DR   EMBL; AB051763; BAB18572.1; -; mRNA.
DR   EMBL; DQ640499; ABF70199.1; -; Genomic_DNA.
DR   EMBL; AC005067; AAD45961.1; -; Genomic_DNA.
DR   EMBL; AC006330; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC034277; AAH34277.1; ALT_INIT; mRNA.
DR   PIR; A33421; A60557.
DR   RefSeq; NP_000932.3; NM_000941.2.
DR   UniGene; Hs.354056; -.
DR   PDB; 1B1C; X-ray; 1.93 A; A=61-241.
DR   PDB; 3FJO; X-ray; 2.50 A; A=232-677.
DR   PDB; 3QE2; X-ray; 1.75 A; A/B=64-677.
DR   PDB; 3QFC; X-ray; 1.80 A; A/B=64-677.
DR   PDB; 3QFR; X-ray; 2.40 A; A/B=64-677.
DR   PDB; 3QFS; X-ray; 1.40 A; A=241-677.
DR   PDB; 3QFT; X-ray; 1.40 A; A=241-677.
DR   PDB; 5EMN; X-ray; 2.20 A; A/B=64-677.
DR   PDB; 5FA6; X-ray; 2.30 A; A/B=64-677.
DR   PDBsum; 1B1C; -.
DR   PDBsum; 3FJO; -.
DR   PDBsum; 3QE2; -.
DR   PDBsum; 3QFC; -.
DR   PDBsum; 3QFR; -.
DR   PDBsum; 3QFS; -.
DR   PDBsum; 3QFT; -.
DR   PDBsum; 5EMN; -.
DR   PDBsum; 5FA6; -.
DR   ProteinModelPortal; P16435; -.
DR   SMR; P16435; -.
DR   BioGrid; 111443; 36.
DR   DIP; DIP-29682N; -.
DR   IntAct; P16435; 10.
DR   MINT; MINT-1212161; -.
DR   STRING; 9606.ENSP00000419970; -.
DR   ChEMBL; CHEMBL2169731; -.
DR   DrugBank; DB03461; 2'-Monophosphoadenosine 5'-Diphosphoribose.
DR   DrugBank; DB00865; Benzphetamine.
DR   DrugBank; DB00694; Daunorubicin.
DR   DrugBank; DB00997; Doxorubicin.
DR   DrugBank; DB01466; Ethylmorphine.
DR   DrugBank; DB03147; Flavin adenine dinucleotide.
DR   DrugBank; DB00166; Lipoic Acid.
DR   DrugBank; DB00305; Mitomycin.
DR   DrugBank; DB00665; Nilutamide.
DR   DrugBank; DB00698; Nitrofurantoin.
DR   DrugBank; DB03247; Riboflavin Monophosphate.
DR   iPTMnet; P16435; -.
DR   PhosphoSitePlus; P16435; -.
DR   SwissPalm; P16435; -.
DR   BioMuta; POR; -.
DR   DMDM; 2851393; -.
DR   EPD; P16435; -.
DR   MaxQB; P16435; -.
DR   PaxDb; P16435; -.
DR   PeptideAtlas; P16435; -.
DR   PRIDE; P16435; -.
DR   DNASU; 5447; -.
DR   Ensembl; ENST00000394893; ENSP00000378355; ENSG00000127948.
DR   Ensembl; ENST00000412064; ENSP00000404731; ENSG00000127948.
DR   Ensembl; ENST00000412521; ENSP00000409238; ENSG00000127948.
DR   Ensembl; ENST00000414186; ENSP00000399327; ENSG00000127948.
DR   Ensembl; ENST00000418341; ENSP00000389719; ENSG00000127948.
DR   Ensembl; ENST00000432753; ENSP00000389409; ENSG00000127948.
DR   Ensembl; ENST00000439963; ENSP00000390540; ENSG00000127948.
DR   Ensembl; ENST00000449920; ENSP00000399556; ENSG00000127948.
DR   Ensembl; ENST00000453773; ENSP00000395813; ENSG00000127948.
DR   Ensembl; ENST00000454934; ENSP00000414263; ENSG00000127948.
DR   Ensembl; ENST00000461988; ENSP00000419970; ENSG00000127948.
DR   GeneID; 5447; -.
DR   KEGG; hsa:5447; -.
DR   UCSC; uc003udy.4; human.
DR   CTD; 5447; -.
DR   DisGeNET; 5447; -.
DR   GeneCards; MIR4651; -.
DR   GeneCards; POR; -.
DR   GeneReviews; POR; -.
DR   HGNC; HGNC:9208; POR.
DR   HPA; CAB004372; -.
DR   HPA; HPA010136; -.
DR   MalaCards; POR; -.
DR   MIM; 124015; gene.
DR   MIM; 201750; phenotype.
DR   MIM; 613571; phenotype.
DR   neXtProt; NX_P16435; -.
DR   Orphanet; 95699; Congenital adrenal hyperplasia due to cytochrome P450 oxidoreductase deficiency.
DR   PharmGKB; PA33532; -.
DR   eggNOG; KOG1158; Eukaryota.
DR   eggNOG; COG0369; LUCA.
DR   HOGENOM; HOG000282027; -.
DR   HOVERGEN; HBG000432; -.
DR   InParanoid; P16435; -.
DR   KO; K00327; -.
DR   PhylomeDB; P16435; -.
DR   TreeFam; TF105719; -.
DR   BioCyc; MetaCyc:HS05140-MONOMER; -.
DR   BRENDA; 1.6.2.4; 2681.
DR   Reactome; R-HSA-211897; Cytochrome P450 - arranged by substrate type.
DR   SABIO-RK; P16435; -.
DR   ChiTaRS; POR; human.
DR   EvolutionaryTrace; P16435; -.
DR   GeneWiki; Cytochrome_P450_reductase; -.
DR   GenomeRNAi; 5447; -.
DR   PRO; PR:P16435; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   Bgee; ENSG00000127948; -.
DR   CleanEx; HS_POR; -.
DR   ExpressionAtlas; P16435; baseline and differential.
DR   Genevisible; P16435; HS.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; IEA:Ensembl.
DR   GO; GO:0004128; F:cytochrome-b5 reductase activity, acting on NAD(P)H; IEA:Ensembl.
DR   GO; GO:0009055; F:electron carrier activity; IEA:Ensembl.
DR   GO; GO:0019899; F:enzyme binding; IEA:Ensembl.
DR   GO; GO:0050660; F:flavin adenine dinucleotide binding; IEA:Ensembl.
DR   GO; GO:0010181; F:FMN binding; IEA:Ensembl.
DR   GO; GO:0016787; F:hydrolase activity; IEA:Ensembl.
DR   GO; GO:0047726; F:iron-cytochrome-c reductase activity; IEA:Ensembl.
DR   GO; GO:0050661; F:NADP binding; IEA:Ensembl.
DR   GO; GO:0003958; F:NADPH-hemoprotein reductase activity; IDA:BHF-UCL.
DR   GO; GO:0008941; F:nitric oxide dioxygenase activity; IEA:Ensembl.
DR   GO; GO:0009437; P:carnitine metabolic process; IEA:Ensembl.
DR   GO; GO:0090346; P:cellular organofluorine metabolic process; IDA:BHF-UCL.
DR   GO; GO:0071372; P:cellular response to follicle-stimulating hormone stimulus; IEA:Ensembl.
DR   GO; GO:0071375; P:cellular response to peptide hormone stimulus; IEA:Ensembl.
DR   GO; GO:0070988; P:demethylation; IEA:Ensembl.
DR   GO; GO:0019395; P:fatty acid oxidation; IEA:Ensembl.
DR   GO; GO:0009812; P:flavonoid metabolic process; IEA:Ensembl.
DR   GO; GO:0018393; P:internal peptidyl-lysine acetylation; IEA:Ensembl.
DR   GO; GO:0043154; P:negative regulation of cysteine-type endopeptidase activity involved in apoptotic process; IEA:Ensembl.
DR   GO; GO:0060192; P:negative regulation of lipase activity; IEA:Ensembl.
DR   GO; GO:0043602; P:nitrate catabolic process; IEA:Ensembl.
DR   GO; GO:0046210; P:nitric oxide catabolic process; IEA:Ensembl.
DR   GO; GO:0055114; P:oxidation-reduction process; IDA:BHF-UCL.
DR   GO; GO:0045542; P:positive regulation of cholesterol biosynthetic process; IEA:Ensembl.
DR   GO; GO:0032332; P:positive regulation of chondrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0032770; P:positive regulation of monooxygenase activity; IDA:BHF-UCL.
DR   GO; GO:0045880; P:positive regulation of smoothened signaling pathway; IEA:Ensembl.
DR   GO; GO:0090031; P:positive regulation of steroid hormone biosynthetic process; IEA:Ensembl.
DR   GO; GO:0003420; P:regulation of growth plate cartilage chondrocyte proliferation; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0007584; P:response to nutrient; IEA:Ensembl.
DR   GO; GO:0006805; P:xenobiotic metabolic process; TAS:Reactome.
DR   Gene3D; 3.40.50.360; -; 1.
DR   HAMAP; MF_03212; NCPR; 1.
DR   InterPro; IPR003097; FAD-binding_1.
DR   InterPro; IPR017927; Fd_Rdtase_FAD-bd.
DR   InterPro; IPR001094; Flavdoxin-like.
DR   InterPro; IPR008254; Flavodoxin/NO_synth.
DR   InterPro; IPR001709; Flavoprot_Pyr_Nucl_cyt_Rdtase.
DR   InterPro; IPR029039; Flavoprotein-like_dom.
DR   InterPro; IPR001433; OxRdtase_FAD/NAD-bd.
DR   InterPro; IPR023208; P450R.
DR   InterPro; IPR017938; Riboflavin_synthase-like_b-brl.
DR   Pfam; PF00667; FAD_binding_1; 1.
DR   Pfam; PF00258; Flavodoxin_1; 1.
DR   Pfam; PF00175; NAD_binding_1; 1.
DR   PIRSF; PIRSF000208; P450R; 1.
DR   PRINTS; PR00369; FLAVODOXIN.
DR   PRINTS; PR00371; FPNCR.
DR   SUPFAM; SSF52218; SSF52218; 1.
DR   SUPFAM; SSF63380; SSF63380; 1.
DR   PROSITE; PS51384; FAD_FR; 1.
DR   PROSITE; PS50902; FLAVODOXIN_LIKE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Complete proteome;
KW   Congenital adrenal hyperplasia; Craniosynostosis;
KW   Direct protein sequencing; Disease mutation; Endoplasmic reticulum;
KW   FAD; Flavoprotein; FMN; Membrane; NADP; Oxidoreductase;
KW   Phosphoprotein; Polymorphism; Reference proteome; Transmembrane;
KW   Transmembrane helix.
FT   INIT_MET      1      1       Removed. {ECO:0000269|PubMed:2513880}.
FT   CHAIN         2    677       NADPH--cytochrome P450 reductase.
FT                                /FTId=PRO_0000167596.
FT   TOPO_DOM      2     21       Lumenal. {ECO:0000255|HAMAP-
FT                                Rule:MF_03212}.
FT   TRANSMEM     22     42       Helical. {ECO:0000255|HAMAP-
FT                                Rule:MF_03212}.
FT   TOPO_DOM     43    677       Cytoplasmic. {ECO:0000255|HAMAP-
FT                                Rule:MF_03212}.
FT   DOMAIN       80    224       Flavodoxin-like. {ECO:0000255|HAMAP-
FT                                Rule:MF_03212}.
FT   DOMAIN      279    521       FAD-binding FR-type. {ECO:0000255|HAMAP-
FT                                Rule:MF_03212}.
FT   NP_BIND      86     91       FMN. {ECO:0000255|HAMAP-Rule:MF_03212,
FT                                ECO:0000269|PubMed:10048323,
FT                                ECO:0000269|PubMed:21808038}.
FT   NP_BIND     138    141       FMN. {ECO:0000255|HAMAP-Rule:MF_03212,
FT                                ECO:0000269|PubMed:10048323,
FT                                ECO:0000269|PubMed:21808038}.
FT   NP_BIND     173    182       FMN. {ECO:0000255|HAMAP-Rule:MF_03212,
FT                                ECO:0000269|PubMed:10048323,
FT                                ECO:0000269|PubMed:21808038}.
FT   NP_BIND     454    457       FAD. {ECO:0000255|HAMAP-Rule:MF_03212,
FT                                ECO:0000269|PubMed:19483672,
FT                                ECO:0000269|PubMed:21808038}.
FT   NP_BIND     472    474       FAD. {ECO:0000255|HAMAP-Rule:MF_03212,
FT                                ECO:0000269|PubMed:19483672,
FT                                ECO:0000269|PubMed:21808038}.
FT   NP_BIND     488    491       FAD. {ECO:0000255|HAMAP-Rule:MF_03212,
FT                                ECO:0000269|PubMed:19483672,
FT                                ECO:0000269|PubMed:21808038}.
FT   NP_BIND     596    597       NADP. {ECO:0000255|HAMAP-Rule:MF_03212,
FT                                ECO:0000269|PubMed:21808038}.
FT   NP_BIND     602    606       NADP. {ECO:0000255|HAMAP-Rule:MF_03212,
FT                                ECO:0000269|PubMed:21808038}.
FT   BINDING     208    208       FMN. {ECO:0000255|HAMAP-Rule:MF_03212,
FT                                ECO:0000269|PubMed:10048323,
FT                                ECO:0000269|PubMed:21808038}.
FT   BINDING     298    298       NADP. {ECO:0000255|HAMAP-Rule:MF_03212,
FT                                ECO:0000269|PubMed:21808038}.
FT   BINDING     424    424       FAD. {ECO:0000255|HAMAP-Rule:MF_03212,
FT                                ECO:0000269|PubMed:19483672,
FT                                ECO:0000269|PubMed:21808038}.
FT   BINDING     478    478       FAD. {ECO:0000255|HAMAP-Rule:MF_03212,
FT                                ECO:0000269|PubMed:19483672,
FT                                ECO:0000269|PubMed:21808038}.
FT   BINDING     535    535       NADP. {ECO:0000255|HAMAP-Rule:MF_03212,
FT                                ECO:0000269|PubMed:21808038}.
FT   BINDING     638    638       NADP. {ECO:0000255|HAMAP-Rule:MF_03212,
FT                                ECO:0000269|PubMed:21808038}.
FT   BINDING     676    676       FAD. {ECO:0000255|HAMAP-Rule:MF_03212,
FT                                ECO:0000269|PubMed:19483672,
FT                                ECO:0000269|PubMed:21808038}.
FT   MOD_RES       2      2       N-acetylglycine.
FT                                {ECO:0000269|PubMed:2513880}.
FT   MOD_RES      63     63       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   VARIANT     178    178       Y -> D (in DISPORD; complete loss of
FT                                activity). {ECO:0000269|PubMed:15220035}.
FT                                /FTId=VAR_021154.
FT   VARIANT     225    225       P -> L. {ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_047885.
FT   VARIANT     252    252       D -> N. {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_047886.
FT   VARIANT     284    284       A -> P (in ABS1 and DISPORD; significant
FT                                reduction of activity).
FT                                {ECO:0000269|PubMed:14758361,
FT                                ECO:0000269|PubMed:15220035}.
FT                                /FTId=VAR_021155.
FT   VARIANT     454    454       R -> H (in ABS1 and DISPORD; significant
FT                                reduction of activity).
FT                                {ECO:0000269|PubMed:14758361,
FT                                ECO:0000269|PubMed:15220035,
FT                                ECO:0000269|PubMed:15264278,
FT                                ECO:0000269|PubMed:15483095,
FT                                ECO:0000269|PubMed:27610946}.
FT                                /FTId=VAR_021156.
FT   VARIANT     489    489       V -> E (in ABS1; significant reduction of
FT                                activity). {ECO:0000269|PubMed:14758361}.
FT                                /FTId=VAR_021157.
FT   VARIANT     500    500       A -> V (in dbSNP:rs1057868).
FT                                {ECO:0000269|PubMed:15483095,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:1550342,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_004617.
FT   VARIANT     551    551       R -> Q.
FT                                /FTId=VAR_004618.
FT   VARIANT     566    566       C -> Y (in DISPORD; significant reduction
FT                                of activity).
FT                                {ECO:0000269|PubMed:14758361,
FT                                ECO:0000269|PubMed:15220035}.
FT                                /FTId=VAR_021158.
FT   VARIANT     575    575       Y -> C (in ABS1).
FT                                {ECO:0000269|PubMed:15483095}.
FT                                /FTId=VAR_021159.
FT   VARIANT     605    605       V -> F (in DISPORD; significant reduction
FT                                of activity).
FT                                {ECO:0000269|PubMed:14758361}.
FT                                /FTId=VAR_021160.
FT   VARIANT     609    617       LKQDREHLW -> R (in ABS1).
FT                                /FTId=VAR_021161.
FT   CONFLICT    405    405       M -> L (in Ref. 3; BAB18572).
FT                                {ECO:0000305}.
FT   CONFLICT    518    518       F -> L (in Ref. 1; AAB21814 and 3;
FT                                BAB18572). {ECO:0000305}.
FT   CONFLICT    537    538       VA -> WH (in Ref. 1; AAB21814).
FT                                {ECO:0000305}.
FT   HELIX        69     76       {ECO:0000244|PDB:3QE2}.
FT   STRAND       79     85       {ECO:0000244|PDB:3QE2}.
FT   STRAND       87     89       {ECO:0000244|PDB:3QE2}.
FT   HELIX        90    101       {ECO:0000244|PDB:3QE2}.
FT   HELIX       102    105       {ECO:0000244|PDB:3QE2}.
FT   STRAND      109    112       {ECO:0000244|PDB:3QE2}.
FT   HELIX       114    116       {ECO:0000244|PDB:3QE2}.
FT   HELIX       119    127       {ECO:0000244|PDB:3QE2}.
FT   STRAND      132    138       {ECO:0000244|PDB:3QE2}.
FT   HELIX       141    143       {ECO:0000244|PDB:3QE2}.
FT   HELIX       147    149       {ECO:0000244|PDB:3QE2}.
FT   HELIX       150    158       {ECO:0000244|PDB:3QE2}.
FT   STRAND      167    174       {ECO:0000244|PDB:3QE2}.
FT   STRAND      178    180       {ECO:0000244|PDB:3QE2}.
FT   HELIX       183    194       {ECO:0000244|PDB:3QE2}.
FT   STRAND      198    201       {ECO:0000244|PDB:3QE2}.
FT   STRAND      204    207       {ECO:0000244|PDB:3QE2}.
FT   TURN        208    210       {ECO:0000244|PDB:5EMN}.
FT   HELIX       212    231       {ECO:0000244|PDB:3QE2}.
FT   STRAND      245    249       {ECO:0000244|PDB:3QFS}.
FT   HELIX       255    257       {ECO:0000244|PDB:3QFS}.
FT   STRAND      259    261       {ECO:0000244|PDB:3QFS}.
FT   STRAND      263    265       {ECO:0000244|PDB:3QFS}.
FT   TURN        266    270       {ECO:0000244|PDB:3QFS}.
FT   STRAND      278    280       {ECO:0000244|PDB:3QFS}.
FT   STRAND      282    291       {ECO:0000244|PDB:3QFS}.
FT   STRAND      294    298       {ECO:0000244|PDB:3QFS}.
FT   STRAND      300    306       {ECO:0000244|PDB:3QFS}.
FT   STRAND      319    322       {ECO:0000244|PDB:3QFS}.
FT   HELIX       328    338       {ECO:0000244|PDB:3QFS}.
FT   STRAND      345    352       {ECO:0000244|PDB:3QFS}.
FT   STRAND      360    366       {ECO:0000244|PDB:3QFS}.
FT   HELIX       367    373       {ECO:0000244|PDB:3QFS}.
FT   HELIX       383    389       {ECO:0000244|PDB:3QFS}.
FT   HELIX       390    392       {ECO:0000244|PDB:3QFS}.
FT   HELIX       396    406       {ECO:0000244|PDB:3QFS}.
FT   STRAND      407    409       {ECO:0000244|PDB:5FA6}.
FT   HELIX       410    419       {ECO:0000244|PDB:3QFS}.
FT   TURN        420    424       {ECO:0000244|PDB:3QFS}.
FT   HELIX       427    433       {ECO:0000244|PDB:3QFS}.
FT   HELIX       441    447       {ECO:0000244|PDB:3QFS}.
FT   STRAND      454    457       {ECO:0000244|PDB:3QFS}.
FT   TURN        462    464       {ECO:0000244|PDB:3QFS}.
FT   STRAND      468    474       {ECO:0000244|PDB:3QFS}.
FT   STRAND      477    479       {ECO:0000244|PDB:3QFS}.
FT   STRAND      485    487       {ECO:0000244|PDB:3QFS}.
FT   HELIX       489    495       {ECO:0000244|PDB:3QFS}.
FT   TURN        501    503       {ECO:0000244|PDB:3QE2}.
FT   STRAND      508    514       {ECO:0000244|PDB:3QFS}.
FT   STRAND      528    531       {ECO:0000244|PDB:3QFS}.
FT   HELIX       534    537       {ECO:0000244|PDB:3QFS}.
FT   HELIX       538    553       {ECO:0000244|PDB:3QFS}.
FT   STRAND      560    567       {ECO:0000244|PDB:3QFS}.
FT   TURN        569    571       {ECO:0000244|PDB:3QFS}.
FT   HELIX       576    584       {ECO:0000244|PDB:3QFS}.
FT   STRAND      587    595       {ECO:0000244|PDB:3QFS}.
FT   STRAND      598    601       {ECO:0000244|PDB:3QFS}.
FT   HELIX       605    611       {ECO:0000244|PDB:3QFS}.
FT   HELIX       613    621       {ECO:0000244|PDB:3QFS}.
FT   STRAND      625    631       {ECO:0000244|PDB:3QFS}.
FT   TURN        632    634       {ECO:0000244|PDB:3QFS}.
FT   HELIX       635    650       {ECO:0000244|PDB:3QFS}.
FT   HELIX       655    667       {ECO:0000244|PDB:3QFS}.
FT   STRAND      670    676       {ECO:0000244|PDB:3QFS}.
SQ   SEQUENCE   677 AA;  76690 MW;  2F7D4B9CDFDF5A74 CRC64;
     MGDSHVDTSS TVSEAVAEEV SLFSMTDMIL FSLIVGLLTY WFLFRKKKEE VPEFTKIQTL
     TSSVRESSFV EKMKKTGRNI IVFYGSQTGT AEEFANRLSK DAHRYGMRGM SADPEEYDLA
     DLSSLPEIDN ALVVFCMATY GEGDPTDNAQ DFYDWLQETD VDLSGVKFAV FGLGNKTYEH
     FNAMGKYVDK RLEQLGAQRI FELGLGDDDG NLEEDFITWR EQFWPAVCEH FGVEATGEES
     SIRQYELVVH TDIDAAKVYM GEMGRLKSYE NQKPPFDAKN PFLAAVTTNR KLNQGTERHL
     MHLELDISDS KIRYESGDHV AVYPANDSAL VNQLGKILGA DLDVVMSLNN LDEESNKKHP
     FPCPTSYRTA LTYYLDITNP PRTNVLYELA QYASEPSEQE LLRKMASSSG EGKELYLSWV
     VEARRHILAI LQDCPSLRPP IDHLCELLPR LQARYYSIAS SSKVHPNSVH ICAVVVEYET
     KAGRINKGVA TNWLRAKEPA GENGGRALVP MFVRKSQFRL PFKATTPVIM VGPGTGVAPF
     IGFIQERAWL RQQGKEVGET LLYYGCRRSD EDYLYREELA QFHRDGALTQ LNVAFSREQS
     HKVYVQHLLK QDREHLWKLI EGGAHIYVCG DARNMARDVQ NTFYDIVAEL GAMEHAQAVD
     YIKKLMTKGR YSLDVWS
//
